Clinical Trial Update: PVX4 for the Treatment of Human Papilloma Virus (HPV)16+ Cervical Dysplasia [Phase 2]

View source ↗

Summary

PVX4 is being studied in a Phase 2 trial for cervical intraepithelial neoplasia grade 2/3 associated with HPV-16 infection, and the study is not yet recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cervical Intraepithelial Neoplasia
• Human Papillomavirus Infection Hpv Type 16

Drugs mentioned

• PVX4

Snippet

Sponsor: PapiVax Biotech, Inc. | Conditions: Cervical Intraepithelial Neoplasia Grade 2/3, Human Papilloma Virus Infection Type 16 | Phase 2 | Status: NOT_YET_RECRUITING